Press Release

http://www.mdtoday.co.kr/mdtoday/index.html?no=339101

http://www.mdtoday.co.kr/mdtoday/index.html?no=339101 Recently, China has innovated various drug and medical regulations, and multinational pharmaceutical companies are advancing into China one after another. While it is emerging as a global market, new Korean drugs are attracting attention in the Chinese market. According to the Korea Drug Development Fund, Biocentury and Bayhelix Group held the ‘Biocentury China Healthcare […]

http://www.yakup.com/news/index.html?mode=view&cat=12&nid=224247

http://www.yakup.com/news/index.html?mode=view&cat=12&nid=224247 At the 5th ‘China Summit’, new Korean drug development performance was introduced. Biocentury and Bayhelix Group held the ‘BioCentury-China Healthcare Summit (China Summit).’ Four hundred and fifty pharmaceutical and bio-pharma leaders from 16 countries gathered together at the China Summit, which was held in Shanghai, China from November 13 to November 14, and discussed […]

http://www.biospectator.com/view/news_view.php?varAtcId=6438

http://www.biospectator.com/view/news_view.php?varAtcId=6438 Joint research with Bio-Pharm Solutions is evaluating the efficacy of the drug in zebrafish with epileptic seizure. Woojung Bio announced on October 25 that it began epilepsy medicine screening using zebrafish jointly with Bio-Pharm Solutions, a CNS rare disease medicine developer.

http://www.etoday.co.kr/news/section/newsview.php?idxno=1678789

http://www.etoday.co.kr/news/section/newsview.php?idxno=1678789 Woojung Bio announced on October 25 that it is conducting epilepsy drug screening using zebrafish jointly with Bio-Pharm Solutions, a developer of medicine for rare diseases of the central nervous system (CNS). According to Woojung Bio, Prof. Kim Cheol-hee’s team of Chungnam National University and Woojung Bio cooperated in a national project last year […]

http://medipana.com/news/news_viewer.asp?NewsNum=219029&MainKind=A&NewsKind=5&vCount=12&vKind=1

http://medipana.com/news/news_viewer.asp?NewsNum=219029&MainKind=A&NewsKind=5&vCount=12&vKind=1 Once developed, they have great benefits in terms of system and prices. Many Korean companies are conducting clinical trials in the US and Europe. Not only global pharmaceutical companies, but also Korean pharmaceutical companies are rushing into the rare disease market with high unmet demands. Due to the characteristics of ‘rare diseases,’ it is […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

Bio-Pharm Solutions

145, Gwanggyo-ro, Yeongtong-gu, Suwon,
Gyeonggi-do, 16229, Korea
6F, C Bldg, Advanced Institute of Convergence Technology

CONTACT

Tel: 82-31-888-9608
Fax: 82-31-888-9601

MORE

Careers: shkim@b-psol.com
Clinical Trials: hsshin@b-psol.com
Investor Inquiries: uklee@b-psol.com
BD Partnering: uklee@b-psol.com